Several data in NSCLC correlated high levels of sLAG3 to the early diagnosis and staging of NSCLC (39, 40) and we demonstrated that non-responding NSCLC patients treated with nivolumab had increasing levels of LAG3 after therapy confirming the results observed in naïve patients (26) such as in other solid tumors (41). This evidence concerns the gene LAG3 and non-small cell lung carcinoma.